AJNA BioSciences

We recently published a list of Top 8 AI News Updates Investors Should Not Miss. In this article, we are going to take a look at where Nano-X Imaging Ltd. (NASDAQ:NNOX) stands against other top AI news updates investors should not miss.

Data from AbbVie and Johnson & Johnson will fine-tune OpenFold3 in a confidentiality-preserving environment, powered by Apheris.

Another company involved in using AI to repurpose failed drugs - as well as drugs that have already been approved - is BioXcel Therapeutics. Unlike Ignota, however, the company focuses on compounds that have already demonstrated safety in prior clinical trials, but have been discontinued by their developers for various other reasons.

Johnson & Johnson signed a multibillion-dollar contract with ChemImage in 2019. The two companies will face off in court next week.

UNC Charlotte researchers are contributing to pioneering breakthroughs in cancer therapeutics, communicable disease forecasting and prevention, optical applications for health care, and use of AI and other innovative computational tools — and more.

Beyond speed, AI has also helped reduce costs. Conventional methods required nearly $35,000 per genome analysis, but AI-driven models running on GPUs have lowered the cost to under $2,000, making high-quality genomic research more accessible.

In a recent interview with Fierce Biotech's Chris Hayden, Fortrea's Chief Technology and Data Officer Alaric Jackson discussed the growing role of AI in clinical trials. | Fortrea's CTO discusses AI's expanding role in clinical trials,

Biotechnology innovations are revolutionizing healthcare with AI, data science, and automation, leading to more precise and personalized treatments.